Navigation Links
GeoVax Labs Reports Fourth Quarter and Year-End 2010 Financial Results
Date:2/25/2011

ATLANTA, Feb. 25, 2011 /PRNewswire/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based biotechnology company that creates, develops, and tests innovative HIV/AIDS vaccines, today announced its financial results for the fourth quarter and year ended December 31, 2010.

GeoVax reported a net loss of $478,784 for the fourth quarter ended December 31, 2010, as compared to a net loss of $843,275 for the comparable period in 2009. For the full year of 2010, the Company reported a net loss of $2,747,328 as compared to a net loss of $3,284,252 in 2009.  Grant revenues were $5,185,257 and $3,668,195 for the years ended December 31, 2010 and 2009, respectively.  As of December 31, 2010, the Company reported cash balances totaling $1,079,087.  Summarized financial information is attached.  Further information concerning the Company's financial position and results of operations are included in its Annual Report on Form 10-K, expected to be filed with the Securities and Exchange Commission before March 31, 2011.

Highlights of the Company's scientific and clinical progress during 2010 are as follows:

  • Early results from the Phase 2a trial for the preventative version of GeoVax's vaccine indicated an excellent safety profile and highly reproducible immunogenicity.  This trial was expanded to include testing of an additional, simpler vaccine regimen, and we expect patient enrollment and vaccinations to be completed during 2011.

  • During 2010, GeoVax began recruiting and screening patients for a Phase 1/2 trial for the therapeutic version of our vaccine.  In order to accelerate enrollment in this important study, a second site at the University of Alabama, Birmingham was recently added to complement the enrollment already underway in Atlanta.

  • We reported preclinical results using GM-CSF (granulocyte/macrophage
    '/>"/>

  • SOURCE GeoVax Labs, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
    2. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
    3. GeoVax Presents Data at AIDS Vaccine 2008 Conference
    4. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
    5. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
    6. GeoVax to Present at the BIO CEO & Investor Conference 2009
    7. GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference
    8. GeoVax Update Provided at the BIO CEO & Investor Conference 2009
    9. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results
    10. GeoVax Labs, Inc. Announces First Quarter Financial Results
    11. GeoVax to Exhibit at the 2009 BIO International Convention
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/21/2014)... HONG KONG , Aug. 21, 2014  China Cord ... today announced its plan to release financial results for ... August 28, 2014, after market close in the US.  ... call at 8:00 a.m. ET on Friday, August 29, ... brief overview of the Company,s recent developments, followed by ...
    (Date:8/21/2014)... St. Louis, MO (PRWEB) August 21, 2014 ... premier, full service biopharmaceutical contract development and manufacturing ... selected by Progenics Pharmaceuticals, Inc., an oncology company ... targeting and treating cancer, to manufacture the anti-prostate ... Progenics’ PSMA ADC product candidate. Under the ...
    (Date:8/20/2014)... An analysis of patented university inventions licensed to ... path to commercialization. To open these roadblocks, the ... results during the discovery stage could lead to ... are frequently derived from discoveries made in university ... well known during clinical trials, which have a ...
    (Date:8/20/2014)... California (PRWEB) August 20, 2014 ... develop and apply the most complete climate and ... and demanding climate change issues. , Eight national ... forces with the National Center for Atmospheric Research, ... the new effort. Other participating national laboratories include ...
    Breaking Biology Technology:China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3
    ... ST. LOUIS, May 16 Stereotaxis, Inc. (Nasdaq:,STXS), ... Officer, will,present at the Seventh Annual JMP Securities ... 2008 at 12:00 p.m. Pacific Time., Attendance ... audio,presentation will be webcast live and remain available ...
    ... shown that they can use a red blood cell ... , "It turns around the rules of nanotechnology, by ... assistant professor in the Department of Biomedical Engineering at ... student Chawin Ounkomol. , An atomic force microscope uses ...
    ... esophagus eliminated in 90 percent ... ... Inc., the,global technology leader for treating precancerous conditions of the,digestive tract, ... study were free of the highest-risk of Barrett,s,esophagus after having a ...
    Cached Biology Technology:New Study Reports That Ablative Therapy With HALO360 Device Effectively Treats Highest-Risk Category of Barrett's Esophagus 2New Study Reports That Ablative Therapy With HALO360 Device Effectively Treats Highest-Risk Category of Barrett's Esophagus 3
    (Date:8/20/2014)... Cancer Institute (HCI) at the University of Utah have ... encodes BCR-ABL, the unregulated enzyme driving the blood cancer ... Society, nearly 6,000 new cases of CML will be ... tyrosine kinase inhibitors (TKIs), target BCR-ABL and are effective ... but control it in a way that allows patients ...
    (Date:8/20/2014)... Using population-based screening outcomes of approximately 3 million ... four researchers at the University of Massachusetts Medical School, ... (SCID) can be successfully implemented across public health newborn ... in the Aug. 20 issue of the Journal ... showed the rate of SCID in newborns is higher ...
    (Date:8/20/2014)... of sunscreen and seawater signals a relaxing trip to ... idyllic beach vacation comes with an environmental hitch. When ... sea, they can become toxic to some of the ... many other marine animals. Their study appears in the ... Antonio Tovar-Sanchez and David Snchez-Quiles point out that other ...
    Breaking Biology News(10 mins):Blueprint for next generation of chronic myeloid leukemia treatment 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3
    ... TORONTO, ON Researchers from the University of Toronto and ... the genes in the fungus that causes Dutch Elm Disease. ... 30 million DNA letters for the fungus Ophiostoma ulmi ... online journal BMC Genomics , could help scientists figure ...
    ... recently voted to scrap the controversial discards policy, which ... fish waste back into the sea because they have ... could have a negative impact on some seabirds, which ... are increasingly reliant on their discards., But they say ...
    ... syndrome who wonder if stress aggravates their intestinal disorder, a ... all in their head. Researchers revealed that while ... and induces the intestinal inflammation that often leads to severe ... Stress has a way of suppressing an important component ...
    Cached Biology News:Discards ban could impact seabird populations 2Study: Probiotics reduce stress-induced intestinal flare-ups 2
    ... sealed isolation chamber provides a safe, ... sterile pharmaceuticals, in accord with USP-797 ... 100 (ISO 5) cleanliness conditions in ... IV rod and tilt-up front panel ...
    ... siRNA Tracker Intracellular Localization Kit with ... forward approach to directly label and ... an efficient yet non-destructive manner, for ... and functional inhibition of target gene ...
    ... The Label IT siRNA Tracker Intracellular ... provides a straight forward approach to ... your design, in an efficient yet ... experiments. Subcellular localization and functional inhibition ...
    Selective media for Salmonella...
    Biology Products: